 |
TSO3 Raises $4 Million through Purchase WarrantsJuly 18, 2007Québec City, July 18, 2007 – TSO3 Inc. (“TSO3”) (TSX: TOS) announces today that it is issuing 1,613,300 new shares as a result of the exercising of an equal amount of purchase warrants at the price of $2.50, allowing the Company to raise $4,033,250. Issued in 2005, these warrants expired July 7, 2007.“We are pleased to raise this additional financing. The largest portion will be directly invested in the sales and marketing department, to accelerate the commercialization of the 125L Ozone Sterilizer,” said Jocelyn Vézina, the Chief Executive Officer of TSO3 Inc. “Today, the North American hospital market is responding positively to the introduction of our ozone sterilization technology. That’s why we must take advantage of the moment to increase our commercialization efforts,” he concluded. About TSO3 TSO3 Inc. is located in Québec City, Québec, Canada, and was founded in 1998. The Company’s mission is to develop and market innovative and comprehensive sterilization solutions. TSO3 has perfected an innovative sterilization process using ozone as the sterilizing agent. The first product based on this technological platform is the 125L Ozone Sterilizer, which is intended for hospital sterilization units. The 125L – named after its 125-litre/4.3-cubic-foot capacity – was designed to sterilize heat-sensitive surgical and diagnostic devices which are expensive and in high demand from the surgical suite. The ozone sterilization process is a safe, efficacious, fast and cost-effective response to evolving sterilization needs. The 125L Ozone Sterilizer by TSO3 has been cleared for commercialization by Health Canada and by the U.S. Food and Drug Administration (FDA). TSO3 currently has more than 60 employees, 27 of whom work in the sales and marketing team. The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties. The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it. -30- Source: TSO3 Inc. Information: Mathieu Claise Interim Director, Corporate Communications and Investor Relations 418 651-0003, Ext. 237 Email: ir@tso3.com |
© 2005-2008 TSO3. All Rights Reserved.
